Recent advances in the management of variceal bleeding

Ihteshamul Haq, Dhiraj Tripathi, Ihteshamul Haq, Dhiraj Tripathi

Abstract

Acute haemorrhage from ruptured gastroesophageal varices is perhaps the most serious consequence of uncontrolled portal hypertension in cirrhotic patients. It represents a medical emergency and is associated with a high morbidity and mortality. In those who survive the initial bleeding event, the risks of further bleeding and other decompensated events remain high. The past 30 years have seen a slow evolution of management strategies that have greatly improved the chances of surviving a variceal haemorrhage. Liver cirrhosis is a multi-staged pathological process and we are moving away from a one-size-fits-all therapeutic approach. Instead there is an increasing recognition that a more nuanced approach will yield optimal survival for patients. This approach seeks to risk stratify patients according to their disease stage. The exact type and timing of treatment offered can then be varied to suit individual patients. At the same time, the toolbox of available therapy is expanding and there is a continual stream of emerging evidence to support the use of endoscopic and pharmacological therapies. In this review, we present a summary of the treatment options for a variety of different clinical scenarios and for when there is failure to control bleeding. We have conducted a detailed literature review and presented up-to-date evidence from either primary randomized-controlled trials or meta-analyses that support current treatment algorithms.

Keywords: acute varices haemorrhage; cirrhosis; non-selective beta-blockers; prophylaxis; variceal band ligation; varices.

Figures

Figure 1.
Figure 1.
Treatment algorithm for the screening and management of gastroesophageal varices. GI, gastrointestinal; OGD, oesophago-gastro-duodenosopy; NSBB, non-selective beta-blockers; VBL, variceal band ligation. Adapted from Bosch J and Sauerbruch T. Esophageal varices: stage dependent treatment algorithm. J Hepatol 2016;64:746–8.
Figure 2.
Figure 2.
Treatment algorithm for the management of acute variceal haemorrhage. NSBB, non-selective beta-blockers; VBL, variceal band ligation; ABCDE, Airway, Breathing, Circulation, Disability, Exposure; OGD, oesophago-gastro-duodenosopy; GOV, gastro-oesophageal varices; IGV, isolated gastric varices; TIPSS, transjugular intrahepatic portosystemic stent-shunt.

References

    1. Tetangco EP, Silva RG, Lerma EV.. Portal hypertension: etiology, evaluation and management. Disease Mon 2016;62:411–26.
    1. Garcia-Pagan JC, Gracia-Sncho J, Bosch J.. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012;57:458–61.
    1. Groszmann RJ, Garcia-Tsao G, Bosch J. et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Eng J Med 2005;353:2254–61.
    1. Ripoll C, Groszmann RJ, Garcia-Tsao G. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481–8.
    1. Garcia-Tsao G, Groszmann RJ, Fisher RL. et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419–24.
    1. Ripoll C, Groszmann RJ, Garcia-Tsao G. et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923–8.
    1. Groszman RJ, Bosch J, Grace ND. et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal haemorrhage. Gastroenterology 1990;99:1401–7.
    1. Feu F, Garcia-Pagan JC, Bosch J. et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056–9.
    1. D’Amico G, Garcia-Pagan JC, Luca A. et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review . Gastroenterology 2006;131:1611–24.
    1. Burroughs AK, Triantos CK.. Predicting failure to control bleeding and mortality in acute variceal bleeding . J Hepatol 2008;53:185–8.
    1. Graham DY, Smith JL.. The course of patients after variceal haemorrhage. Gastroenterology 1981;80:800–9.
    1. Rockall TA, Logan RF, Devlin HB. et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingkom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995;311:222–6.
    1. Jairath V, Rehal S, Logan R. et al. Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. Dig Liver Dis 2014;46:419–26.
    1. de Francis R, Baveno VI faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: Stratifying risk and individualising care for portal hypertension. J Hepatol 2015;63:743–52.
    1. Tripathi D, Stanley AJ, Hayes PC. et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680–704.
    1. Garcia-Tsao G, Abraldes JG, Berzigotti A. et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis and management: 2016 practice guidance by the American Association for the study of liver disease. Hepatology 2017;65:310–35.
    1. Grace ND, Groszmann RJ, Garcia-Tsao G. et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998;28:868–80.
    1. D’Amico G, Pasta L, Morabito A. et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014;39:1180–93.
    1. Pagliaro L, D’Amico G, Pasta L. et al. Portal hypertension in cirrhosis: natural history In: Bosch J, Groszmann RJ (eds). Portal Hypertension: Pathophysiology and Treatment. Oxford: Blackwell Scientific Press, 1994, 72–92.
    1. Groszmann RJ, Garcia-Tsao G, Bosch J, et al.Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254–61.
    1. Merli M, Nicolini G, Angeloni S. et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003;38:266–72.
    1. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988;319:983–9.
    1. Polio J, Groszmann RJ, Reuben A. et al. Portal hypertension ameliorates arterial hypertension in spontaneously hypertensive rats. J Hepatol 1989;8:294–301.
    1. Groszmann RJ, Bosch J, Grace N. et al. Hemodynamic events in a prospective randomized trial of propranolol vs placebo in the prevention of the first variceal hemorrhage. Gastroenterology 1990;99:1401–7.
    1. Casado M, Bosch J, Garcia-Pagan JC. et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998;114:1296–1303.
    1. Feu F, Garcia-Pagan JC, Bosch J. et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056–9.
    1. Abraldes JG, Tarantino I, Turnes J. et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902–8.
    1. Bosch J, Garcia-Pagan JC.. Prevention of variceal rebleeding. Lancet 2003;361:952–4.
    1. El-Serag HB, Everhart JE.. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000;95:3566–73.
    1. D’Amico G, de Franchis R.. Upper digestive bleeding in cirrhosis: post-therapeutic outcome and prognostic indicators. Hepatology 2003;38:599–612.
    1. Carbonell N, Pauwels A, Serfaty L. et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652–9.
    1. Moitinho E, Escorsell A, Bandi JC. et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626–31.
    1. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L. et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004;40:793–801.
    1. Sarin SK, Lahoti D, Saxena SP. et al. Prevalence, classification and natural history of gastric varices—a long term follow up study in 568 portal hypertension patients. Hepatology 1992;16:1323–49.
    1. De Francis R, Primignani M.. Natural history of portal hypertension in patients with cirrhosis. Clin Liv Dis 2001;5:645–63.
    1. Kim T, Shijo H, Kokawa H. et al. Risk factors for haemorrhage from gastric fundal varices. Hepatology 1997;25:307–12.
    1. Tripathi D, Ferguson JW, Therapondos G. et al. Recent advances in the management of bleeding gastric varices. Aliment Pharmacol Ther 2006;24:1–17.
    1. de Francis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosisand therapy in portal hypertension. J Hepatol 2010;53:762–8.
    1. Furuichi Y, Kawai T, Ichimura S. et al. Flexible imaging color enhancement improves visibility of transnasal endoscopic images in diagnosing esophageal varices: a multicenter prospective blinded study. J Dig Dis 2012;13:634–41.
    1. Choe WH, Kim JH, Ko SY. et al. Comparison of transnasal small-caliber vs. peroral conventional esophagogastroduodenoscopy for evaluating varices in unsedated cirrhotic patients. Endoscopy 2011;43:649–56.
    1. McCarty TR, Afinogenova Y, Njei B.. Use of wireless capsule endoscopy for the diagnosis and grading of esophageal varices in patients with portal hypertension—a systemic review and meta-analysis. J Clin Gastroenterol 2017;51:174–82.
    1. Castera L, Pinzani M, Bosch J.. Non-invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696–703.
    1. Vizzutti F, Arena U, Romanelli RG. et al. . Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290–7.
    1. Castera L, Le Bail B, Roudot-Thoraval F. et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 2009;50:59–68.
    1. Abraldes JG, Bureau C, Stefanescu H. et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the ‘Anticipate’ Study. Hepatology 2016;64:2173–84.
    1. Cales P, Oberti F, Payen JL. et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial: French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol 1999;11:741–5.
    1. Merkel C, Marin R, Angeli P. et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476–84.
    1. Sarin SK, Misra SR, Sharma P. et al. . Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial. Hepatol Int 2013;7:248–56.
    1. Bhardwaj A,, Kedarisetty CK,, Vashishtha C. et al. (13 June 2016) Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo controlled trial. Gut, 10.1136/gutjnl-2016–311735.
    1. Garcia-Tsao G, Bosch J.. Varices and variceal hemorrhage in cirrhosis: a new view of an old problem. Clin Gastroenterol Hepatol 2015;13:2109–17.
    1. de Franchis R. Expanding consensus in portal hypertension. J Hepatol 2015;63:743–52.
    1. D’Amico G, Pagliaro L, Bosch J.. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475–505.
    1. Reiberger T, Ulbrich G, Ferlitsch A. et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013;62:1634–41.
    1. Sinagra E, Perricone G, D’Amico M. et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther 2014;39:557–68.
    1. Banares R, Moitinho E, Matilla A. et al. Randomized comparison of long-term varvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36:1367–73.
    1. Banares R, Moitinho E, Piqueras B. et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999;30:79–83.
    1. Tripathi D, Ferguson JW, Kochar N. et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009;50:825–33.
    1. Shah HA, Azam Z, Rauf J. et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol 2014;60:757–64.
    1. Gluud LL, Krag A.. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012;8:CD004544.
    1. Funakoshi N, Duny Y, Valats JC. et al. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Ann Hepatol 2012;11:369–83.
    1. Sarin SK, Wadhawan M, Agarwal SR. et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005;100:797–804.
    1. Hernandez-Gea V, Aracil C, Colomo A. et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers. Am J Gastroenterol 2012;107:418–27.
    1. Longacre AV, Imaeda A, Garcia-Tsao G. et al. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal haemorrhage. Hepatology 2008;47:169–76.
    1. D’Amico G, Pagliaro L, Bosch J.. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332–54.
    1. Navasa M, Chesta J, Bosch J. et al. Reduction of portal pressure by isosorbide-5- mononitrate in patients with cirrhosis: effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989;96:1110–18.
    1. Angelico M, Carli L, Piat C. et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993;104:1460–5.
    1. Garcia-Pagan JC. Isosorbide-5-monitrate (ISMN) vs placebo (PLA) in the prevention of the first variceal bleeding (FVB) in patients with contraindications or intolerance to beta-blockers. J Hepatol 2000;32:28.
    1. Mandorfer M, Reiberger T.. Beta-blockers and cirrhosis, 2016. Dig Liver Dis 2017;49:3–10.
    1. Quraishi MN, Khan F, Tripathi D.. How we manage variceal haemorrhage in cirrhotic patients. Pol Arch Med Wewn 2016;126:174–84.
    1. Serste T, Melot C, Francoz C. et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017–22.
    1. Krag A, Wiest R, Albillos A. et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61:967–9.
    1. Krag A, Bendtsen F, Henriksen JH. et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105–10.
    1. Leithead JA, Rajoriya N, Tehami N. et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015;64:1111–19.
    1. Mandorfer M, Bota S, Schwabl P. et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014;146:1680–90.e1.
    1. Bossen L, Krag A, Vilstrup H. et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three randomized controlled trials with 1198 patients. Hepatology 2016;63:1968–76.
    1. Abraldes JG, Villanueva C, Banares R. et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008;48:229–36.
    1. Bambha K, Kim WR, Pedersen R. et al. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 2008;57:814–20.
    1. Amitrano L, Guardascione MA, Manguso F. et al. The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors. Am J Gastroenterol 2012;107:1872–8.
    1. Hunter SS, Hamdy S.. Predictors of early re-bleeding and mortality after acute variceal haemorrhage. Arab J Gastroenterol 2013;14:63–7.
    1. Fortune B, Garcia-Tsao G, Ciarleglio M. et al. Child-Turcotte-Pugh Class is best at stratifying risk in variceal hemorrhage: analysis of a US multicenter prospective study. J Clin Gastroenterol 2017;51:446–53.
    1. Reverter E, Tandon P, Augustin S. et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology 2014;146:412–19.
    1. Villanueva C, Colomo A, Bosch A. et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11–21.
    1. Tripodi A, Mannucci PM.. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147–56.
    1. Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol (N Y) 2012;8:513–20.
    1. Bendtsen F, D’Amico G, Rusch E. et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol 2014;61:252–9.
    1. Wells M, Chande N, Adams P. et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012;35:1267–78.
    1. Ioannou G, Doust J, Rockey DC.. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003;1:CD002147.
    1. Azam Z, Hamid S, Jafri W. et al. Short course adjuvant terlipressin in acute variceal bleeding: a randomized double blind dummy controlled trial. J Hepatol 2012;56:819–24.
    1. Seo YS, Park SY, Kim MY. et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014;60:954–63.
    1. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F. et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding—an updated Cochrane review. Aliment Pharmacol Ther 2011;34:509–18.
    1. Tandon P, Abraldes JG, Keough A. et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol 2015;13:1189–96.
    1. Cheung J, Soo I, Bastiampillai R. et al. Urgent vs. non-urgent endoscopy in stable acute variceal bleeding. Am J Gastroenterol 2009;104:1125–9.
    1. Chen PH, Chen WC, Hou MC. et al. Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study. J Hepatol 2012;57:1207–13.
    1. Laine L, Cook D.. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995;123:280–7.
    1. Banares R, Albillos A, Rincon D. et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609–15.
    1. Panes J, Teres J, Bosch J. et al. Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices: results in 151 consecutive episodes. Dig Dis Sci 1988;33:454–9.
    1. Teres J, Cecilia A, Bordas JM. et al. Esophageal tamponade for bleeding varices: controlled trial between the Sengstaken-Blakemore tube and the Linton-Nachlas tube. Gastroenterology 1978;75:566–9.
    1. Escorsell A, Pavel O, Cardenas A. et al. Esophageal balloon tamponade versus esophageal stent in controllong acute reftractory variceal bleeding: a multicentre randomised controlled trial. Hepatology 2016;63:1957–67.
    1. Vangeli M, Patch D, Burroughs AK.. Salvage tips for uncontrolled variceal bleeding. J Hepatol 2002;37:703–4.
    1. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L. et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004;40:793–801.
    1. Garcia-Pagan JC, Caca K, Bureau C. et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370–9.
    1. Garcia-Pagan JC, Di PM, Caca K. et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013;58:45–50.
    1. Rudler M, Cluzel P, Corvec TL. et al. Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival. Aliment Pharmacol Ther 2014;40:1074–80.
    1. Sanyal AJ, Freedman AM, Luketic VA. et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal haemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:138–46.
    1. McCormick PA, Dick R, Panagou EB. et al. Emergency transjugular intrahepatic portosystemic stent shunting as a salvage treatment for uncontrolled variceal hemorrhage. Br J Surg 1994;81:1324–7.
    1. Orloff MJ, Orloff MS, Orloff SL. et al. Three decades of experience with emergency portacaval shunt for acutely bleeding esophageal varices in 400 unselected patients with cirrhosis of the liver. J Am Coll Surg 1995;180:257–72.
    1. Orloff MJ, Vaida F, Haynes KS. et al. Randomized controlled trial of emergency transjugular intrahepatic portosystemic shunt versus emergency portacaval shunt treatment of acute bleeding esophageal varices in cirrhosis. J Gastrointest Surg 2012;16:2094–2111.
    1. Puente A, Hernandez-Gea V, Graupera I. et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int 2014;34:823–33.
    1. Abraldes JG, Villanueva C, Aracil C. et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016;150: 1160–70.
    1. Pollo-Flores P, Soldan M, Santos UC. et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis 2015;47:957–63.
    1. Mohanty A, Tate JP, Garcia-Tsao G.. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 2016;150:430–440.e1.
    1. Tripathi D, Ferguson JW, Therapondos JN. et al. Review article: recent advances in the management of bleeding gastric varices. Aliment Pharmacol Ther 2006;24:1–17.
    1. Mishra SR, Sharma BC, Kumar A. et al. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol 2011;54:1161–7.
    1. Rios CE,, Seron P,, Gisbert JP. et al. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev 2015;5:CD010180.
    1. Smith MR, Tidswell R, Tripathi D.. Outcomes of endoscopic human thrombin injection in the management of gastric varices. Eur J Gastroenterol Hepatol 2014;26: 846–52.
    1. Tripathi D, Therapondos G, Jackson E. et al. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations. Gut 2002;51:270–4.
    1. Lo GH, Liang HL, Chen WC. et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007;39:679–85.
    1. Krahenbuhl L, Seiler CA, Buchler MW.. Variceal hemorrhage in portal hypertension: role of surgery in the acute and elective situation. Schweiz Med Wochenschr 1999;129:631–8.
    1. Tsuchida S, Ku Y, Fukumoto T. et al. Isolated gastric varices resulting from iatrogenic splenic vein occlusion: report of a case. Surg Today 2003;33:542–4.
    1. McDermott VG, England RE, Newman GE.. Case report: bleeding gastric varices secondary to splenic vein thrombosis successfully treated by splenic artery embolization. Br J Radiol 1995;68:928–30.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe